Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB

Cancer

Last data update: Mar 30, 2023. (Total: 59025 Documents since 2012)
   dataset      
Filtered By:

Previous    

Records 1 - 15 (of 15 Records)

Query Trace: Melanoma[original query]>>Guidelines Related[Product Type]
Early Detection and Prognostic Assessment of Cutaneous Melanoma Consensus on Optimal Practice and the Role of Gene Expression Profile Testing
MK Sabet et al, JAMA Dermatology, March 15, 2023
Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group.
Farberg Aaron S et al. Dermatology and therapy 2022
Prognostic Gene Expression Profiling in Cutaneous Melanoma Identifying the Knowledge Gaps and Assessing the Clinical Benefit
D Grossman et al, JAMA Dermatology, July 29, 2020
[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].
Rose C et al. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2017 Sep 68(9) 749-761
[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].
Rose C et al. Der Pathologe 2017 Feb 38(1) 49-61
Guidelines of care for the management of primary cutaneous melanoma.
Swetter Susan M et al. Journal of the American Academy of Dermatology 2019 80(1) 208-250
Local Coverage Determination (LCD): Genetic Testing for Lynch Syndrome (L34912)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): BRCA1 and BRCA2 Genetic Testing (L36715)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): BRCA1 and BRCA2 Genetic Testing (L36499)
The U.S. Centers for Medicare & Medicaid Services
PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.
Schultz Kris Ann P et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Jun 23(12) e76-e82
Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement.
, et al. JAMA 2016 7 0. (4) 429-35
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
TOP